Corcept Therapeutics

Corcept Therapeutics

Biotechnology Research

Redwood City, California 36,144 followers

Pioneering the discovery and development of cortisol modulators.

Über uns

At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept.

Website
http://www.corcept.com
Industrie
Biotechnology Research
Größe des Unternehmens
201-500 Mitarbeiter
Hauptsitz
Redwood City, California
Typ
Öffentliches Unternehmen
Gegründet
1998

Standorte

Employees at Corcept Therapeutics

Aktualisierungen

Ähnliche Seiten

Jobs durchsuchen

Finanzierung

Corcept Therapeutics 8 total rounds

Letzte Runde

Eigenkapital nach dem IPO

US$ 525.3K

Siehe mehr Informationen auf crunchbase